Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b, Multicenter, Open-Label, Randomized Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin (± Pegylated Interferon) in Subjects With Chronic Genotype 1, 2, 3 and 6 HCV Infection

NCT02021643 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT02021643
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02021643 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b, Multicenter, Open-Label, Randomized Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin (± Pegylated Interferon) in Subjects With Chronic Genotype 1, 2, 3 and 6 HCV Infection
Lead sponsor
Gilead Sciences
Phase
Phase 3
Overall status
Completed
Start date
December 10, 2013
Completion date
November 3, 2016
Enrollment
687 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hcv infection